These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21646302)

  • 41. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.
    Sanna S; Busonero F; Maschio A; McArdle PF; Usala G; Dei M; Lai S; Mulas A; Piras MG; Perseu L; Masala M; Marongiu M; Crisponi L; Naitza S; Galanello R; Abecasis GR; Shuldiner AR; Schlessinger D; Cao A; Uda M
    Hum Mol Genet; 2009 Jul; 18(14):2711-8. PubMed ID: 19419973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic Variations in Bilirubin Metabolism Genes and Their Association with Unconjugated Hyperbilirubinemia in Adults.
    Chiddarwar AS; D'Silva SZ; Colah RB; Ghosh K; Mukherjee MB
    Ann Hum Genet; 2017 Jan; 81(1):11-19. PubMed ID: 27943244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Genetic marker of statin-induced rhabdomyolysis].
    Chiba K; Morimoto K
    Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
    Hartkoorn RC; Kwan WS; Shallcross V; Chaikan A; Liptrott N; Egan D; Sora ES; James CE; Gibbons S; Bray PG; Back DJ; Khoo SH; Owen A
    Pharmacogenet Genomics; 2010 Feb; 20(2):112-20. PubMed ID: 20051929
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease.
    Jindal C; Kumar S; Choudhari G; Goel H; Mittal B
    Indian J Med Res; 2009 Feb; 129(2):170-5. PubMed ID: 19293444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism.
    van der Deure WM; Friesema EC; de Jong FJ; de Rijke YB; de Jong FH; Uitterlinden AG; Breteler MM; Peeters RP; Visser TJ
    Endocrinology; 2008 Sep; 149(9):4695-701. PubMed ID: 18499754
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
    Chigutsa E; Visser ME; Swart EC; Denti P; Pushpakom S; Egan D; Holford NH; Smith PJ; Maartens G; Owen A; McIlleron H
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4122-7. PubMed ID: 21709081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum bilirubin concentration is modified by UGT1A1 haplotypes and influences risk of type-2 diabetes in the Norfolk Island genetic isolate.
    Benton MC; Lea RA; Macartney-Coxson D; Bellis C; Carless MA; Curran JE; Hanna M; Eccles D; Chambers GK; Blangero J; Griffiths LR
    BMC Genet; 2015 Dec; 16():136. PubMed ID: 26628212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
    Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
    J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
    Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
    J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
    ; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
    N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
    Weiner M; Peloquin C; Burman W; Luo CC; Engle M; Prihoda TJ; Mac Kenzie WR; Bliven-Sizemore E; Johnson JL; Vernon A
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4192-200. PubMed ID: 20660695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
    He YJ; Zhang W; Chen Y; Guo D; Tu JH; Xu LY; Tan ZR; Chen BL; Li Z; Zhou G; Yu BN; Kirchheiner J; Zhou HH
    Clin Chim Acta; 2009 Jul; 405(1-2):49-52. PubMed ID: 19374892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
    Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
    Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
    Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SLCO1B1 polymorphism and oral antidiabetic drugs.
    Kalliokoski A; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study.
    Rantner B; Kollerits B; Anderwald-Stadler M; Klein-Weigel P; Gruber I; Gehringer A; Haak M; Schnapka-Köpf M; Fraedrich G; Kronenberg F
    Clin Chem; 2008 May; 54(5):851-7. PubMed ID: 18375480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identifying Potential Therapeutic Applications and Diagnostic Harms of Increased Bilirubin Concentrations: A Clinical and Genetic Approach.
    Zanussi JT; Zhao J; Dorn CA; Liu G; Feng Q; Wei W; Mosley JD; Stein CM; Kawai VK
    Clin Pharmacol Ther; 2022 Feb; 111(2):435-443. PubMed ID: 34625956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.